BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 35173724)

  • 1. Complement System: An Immunotherapy Target in Colorectal Cancer.
    Talaat IM; Elemam NM; Saber-Ayad M
    Front Immunol; 2022; 13():810993. PubMed ID: 35173724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
    Kamal Y; Schmit SL; Frost HR; Amos CI
    Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.
    Nenkov M; Ma Y; Gaßler N; Chen Y
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.
    Subtil B; Cambi A; Tauriello DVF; de Vries IJM
    Front Immunol; 2021; 12():724883. PubMed ID: 34691029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
    Geller A; Yan J
    Front Immunol; 2019; 10():1074. PubMed ID: 31164885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of immunotherapy to treat colorectal cancer.
    Amin M; Lockhart AC
    Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Modeling the Immune Microenvironment of Colorectal Cancer.
    Yoon PS; Del Piccolo N; Shirure VS; Peng Y; Kirane A; Canter RJ; Fields RC; George SC; Gholami S
    Front Immunol; 2020; 11():614300. PubMed ID: 33643296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
    Li X; Nie J; Mei Q; Han WD
    World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting complement-mediated immunoregulation for cancer immunotherapy.
    Kolev M; Markiewski MM
    Semin Immunol; 2018 Jun; 37():85-97. PubMed ID: 29454575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on colorectal cancer microenvironment, epigenetic and immunotherapy.
    Jin K; Ren C; Liu Y; Lan H; Wang Z
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107041. PubMed ID: 33045561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer.
    Matos AI; Carreira B; Peres C; Moura LIF; Conniot J; Fourniols T; Scomparin A; Martínez-Barriocanal Á; Arango D; Conde JP; Préat V; Satchi-Fainaro R; Florindo HF
    J Control Release; 2019 Aug; 307():108-138. PubMed ID: 31226355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA.
    Liu Y; Wang X
    Clin Transl Oncol; 2021 Sep; 23(9):1923-1933. PubMed ID: 33765255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the Verge: Immunotherapy for Colorectal Carcinoma.
    Oh DY; Venook AP; Fong L
    J Natl Compr Canc Netw; 2015 Aug; 13(8):970-8. PubMed ID: 26285242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.
    Gelderman KA; Hakulinen J; Hagenaars M; Kuppen PJ; Meri S; Gorter A
    Mol Immunol; 2003 Sep; 40(1):13-23. PubMed ID: 12909127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel avenues in immunotherapies for colorectal cancer.
    Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.
    Jacobs J; Smits E; Lardon F; Pauwels P; Deschoolmeester V
    J Immunol Res; 2015; 2015():158038. PubMed ID: 26605342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer.
    Nussbaum YI; Manjunath Y; Suvilesh KN; Warren WC; Shyu CR; Kaifi JT; Ciorba MA; Mitchem JB
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.